Prostate Specific Antigen (PSA) Testing Market to reach 9,701.66 Million by 2030, emerging at a CAGR of 11.2% and forecast 2023-2030
Prostate Specific Antigen (PSA) Testing Market Overview
The global Prostate Specific Antigen (PSA) Testing Market Size was valued at USD 4,166.48 Million in 2022 and is projected to reach around USD 9,701.66 Million by 2030, reflecting a Compound Annual Growth Rate (CAGR) of over 11.2%.
The PSA testing market is experiencing significant growth, driven by factors like rising awareness of prostate cancer and increasing geriatric population.
Prostate Specific Antigen (PSA) Testing Market Drivers
Several factors are propelling the growth of the PSA testing market:
Rising awareness of prostate cancer: Public health initiatives and educational campaigns are increasing awareness of prostate cancer, leading to a greater demand for PSA testing as a screening tool.
Aging population: The global population is aging, with a growing number of men reaching the age group most susceptible to prostate cancer. This demographic shift fuels the demand for PSA testing.
Technological advancements: Advancements in PSA testing technology, such as more sensitive assays, are improving the accuracy of early detection.
Government initiatives: Government healthcare programs promoting early cancer detection can significantly influence Prostate Specific Antigen (PSA) Testing Market Growth.
Prostate Specific Antigen (PSA) Testing Market Key Players
The PSA testing market is moderately competitive with a presence of established players and emerging companies. Some key players include:
Bio-Rad Laboratories, Inc., AdvaCare Pharma, Beckman Coulter, Inc., Proteomedix, Fujirebio (H.U. Group), GE HealthCare, Abcam plc, Lomina AG, BioReference Health, LLC (OPKO Health, Inc.), Laboratory Corporation of America Holdings, and Hanzhou Testsea biotechnology co., LTD.
Prostate Specific Antigen (PSA) Testing Market Segmentation
By Test Type: Preliminary Tests and Confirmatory Tests
By End User: Hospital, Cancer Research Institutes, Diagnostic Laboratory, Ambulatory Surgical Centers, and Others
By Region: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Prostate Specific Antigen (PSA) Testing Market Regional Analysis
The PSA testing market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America currently dominates the market due to high healthcare spending and established screening programs.
However, the Asia Pacific region is expected to witness the fastest growth due to a rising aging population and increasing healthcare expenditure.
Contact us:
Consegic Business intelligence Pvt Ltd.
Contact no: (US) (505) 715-4344
Email: sales@consegicbusinessintelligence.com
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian